Form 4: Amphastar Pharmaceuticals Director Richard K. Prins Reports Stock Transactions

Richard K. Prins, a director at Amphastar Pharmaceuticals, executed stock option exercises and sales on August 12, 2024, resulting in changes to his beneficial ownership.

Summary

• On August 12, 2024, Richard K. Prins, a director of Amphastar Pharmaceuticals, engaged in multiple transactions involving the company's common stock.
• Prins exercised stock options to acquire 3,915 shares at $20.03, 6,004 shares at $20.08, and 7,182 shares at $19.52.
• Concurrently, Prins sold 17,101 shares of common stock at a weighted average price of $43.0706, with individual sales ranging from $43.05 to $43.18.
• Following these transactions, Prins's directly held beneficial ownership of Amphastar Pharmaceuticals common stock decreased to 33,971 shares.
• Prins also continues to hold options to purchase 10,000 shares at each of the strike prices of $20.03, $20.08 and $19.52.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. The director exercised options and sold shares, which is a common practice. It doesn't inherently indicate a positive or negative outlook for the company.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It allows investors to monitor the actions of key individuals within Amphastar Pharmaceuticals.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they reflect insider trading activity, which is often scrutinized by investors.

Key Dates